Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 05338F306 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
FMR LLC
13G/A
|
10.8% |
8/7/2026
Event 7/31/2026
|
||
| FMR LLC | 10.8% | |||
| Abigail P. Johnson | 10.8% | |||
|
Commodore Capital LP
13G
|
9.9% |
6/18/2026
Event 6/11/2026
|
||
| Commodore Capital LP | 9.9% | |||
| Commodore Capital Master LP | 9.9% | |||
| Robert Egen Atkinson | 9.9% | |||
| Michael Kramarz | 9.9% | |||
|
TCG Crossover GP II, LLC
13G
|
7.9% |
5/12/2026
Event 5/5/2026
|
||
| TCG Crossover GP II, LLC | 7.9% | |||
| TCG Crossover Fund II, L.P. | 7.9% | |||
| Chen Yu | 7.9% | |||
|
Deep Track Capital, LP
13G/A
|
6.9% |
8/14/2026
Event 6/30/2026
|
||
| Deep Track Capital, LP | 6.9% | |||
| Deep Track Biotechnology Master Fund, Ltd. | 6.9% | |||
| David Kroin | 6.9% | |||
| BlackRock, Inc. 13G | 6.5% |
7/27/2026
Event 6/30/2026
|
||
|
RA Capital Management, L.P.
13G/A
|
6.3% |
8/14/2026
Event 6/30/2026
|
||
| RA Capital Management, L.P. | 6.3% | |||
| Peter Kolchinsky | 6.3% | |||
| Rajeev Shah | 6.3% | |||
| RA Capital Healthcare Fund, L.P. | 6.3% | |||
|
Caligan Partners LP
13G/A
|
5.9% |
8/14/2026
Event 6/30/2026
|
||
| Caligan Partners LP | 5.9% | |||
| David Johnson | 5.9% | |||
|
Affinity Asset Advisors, LLC
13G/A
|
5.5% |
8/13/2026
Event 6/30/2026
|
||
| Affinity Asset Advisors, LLC | 5.5% | |||
| Michael Cho | 5.5% | |||
| State Street Corp 13G | 5.5% |
8/7/2026
Event 6/30/2026
|
||
|
Biotechnology Value Fund L P
13G/A
|
5.3% |
8/14/2026
Event 6/30/2026
|
||
| Biotechnology Value Fund L P | 2.8% | |||
| BVF I GP LLC | 2.8% | |||
| Biotechnology Value Fund II LP | 2.1% | |||
| BVF II GP LLC | 2.1% | |||
| Biotechnology Value Trading Fund OS LP | 0.4% | |||
| BVF Partners OS Ltd. | 0.4% | |||
| BVF GP Holdings LLC | 4.8% | |||
| BVF Partners L P/IL | 5.3% | |||
| BVF Inc/IL | 5.3% | |||
| Lampert Mark N | 5.3% | |||
|
Point72 Asset Management, L.P.
13G
|
5.2% |
5/26/2026
Event 5/22/2026
|
||
| Point72 Asset Management, L.P. | 5.2% | |||
| Point72 Capital Advisors, Inc. | 5.2% | |||
| Steven A. Cohen | 5.2% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (11) | ||||
|
Avoro Capital Advisors LLC
13G/A
|
4.4% |
8/14/2026
Event 6/30/2026
|
||
| Avoro Capital Advisors LLC | 4.4% | |||
| Behzad Aghazadeh | 4.4% | |||
| Vanguard Group Inc 13G/A | 4.4% |
1/30/2026
Event 12/31/2025
|
||
| Patrick J. Crutcher 13G/A | 4.2% |
8/27/2025
Event 8/6/2025
|
||
|
Ikarian Capital, LLC
13G/A
|
3.8% |
11/14/2025
Event 9/30/2025
|
||
| Ikarian Capital, LLC | 3.8% | |||
| Neil Shahrestani | 3.8% | |||
|
Nantahala Capital Management, LLC
13G/A
|
3.5% |
8/14/2026
Event 6/30/2026
|
||
| Nantahala Capital Management, LLC | 3.5% | |||
| Wilmot B. Harkey | 3.5% | |||
| Daniel Mack | 3.5% | |||
|
Logos Global Management LP
13G/A
|
3.2% |
5/15/2026
Event 3/31/2026
|
||
| Logos Global Management LP | 3.2% | |||
| Logos Global Management GP LLC | 3.2% | |||
| Logos Global Master Fund LP | 3.2% | |||
| Logos GP LLC | 3.2% | |||
| Arsani William | 3.2% | |||
|
SilverArc Capital Management, LLC
13G
|
2.8% |
2/10/2026
Event 12/31/2025
|
||
| SilverArc Capital Management, LLC | 2.8% | |||
| Devesh Gandhi | 2.8% | |||
|
Balyasny Asset Management L.P.
13G/A
|
2.4% |
2/17/2026
Event 12/31/2025
|
||
| Balyasny Asset Management L.P. | 2.4% | |||
| Bam GP LLC | 2.4% | |||
| Balyasny Asset Management Holdings LP | 2.4% | |||
| Dames GP LLC | 2.4% | |||
| Dmitry Balyasny | 2.4% | |||
| OrbiMed Advisors LLC 13G/A | 2.1% |
5/15/2026
Event 3/31/2026
|
||
|
Millennium Management LLC
13G/A
|
0% |
7/6/2026
Event 6/30/2026
|
||
| Millennium Management LLC | 0% | |||
| Millennium Group Management LLC | 0% | |||
| Israel A. Englander | 0% | |||
| T. Rowe Price Investment Management, Inc. 13G/A | 0% |
8/14/2026
Event 6/30/2026
|
||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 4 | 265 | $4.06 k |
| 2026 Q2 | 135 | 72.6 M | $1.34 B |
| 2026 Q1 | 110 | 31.2 M | $466 M |
| 2025 Q4 | 93 | 19.9 M | $361 M |
| 2025 Q3 | 72 | 15.3 M | $195 M |
| 2025 Q2 | 37 | 7.84 M | $39.1 M |
| 2025 Q1 | 35 | 8.26 M | $66.1 M |
| 2024 Q4 | 34 | 7.53 M | $56.0 M |
| 2024 Q3 | 31 | 6.66 M | $63.2 M |
| 2024 Q2 | 24 | 771 k | $9.62 M |
| 2024 Q1 | 22 | 87.6 k | $1.90 M |
| 2023 Q4 | 15 | 23.0 k | $210 k |